STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts

STAAR SURGICAL CO

2025-FY EPS reported -$1.62 vs consensus $0.06 ▼ miss (-2878.7%)

Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.
Cost reductions beat $225M second-half 2025 run rate target; operating expenses lowered significantly.
China EVO ICL demand recovered at mid-single-digit rate in 2025; distributor inventories normalized.
EVO+ received China regulatory approval mid-2025; early demand exceeds expectations; shipments began Nov 2025.
FDA expanded EVO ICL age range to 21-60 in US, adding ~8M potential patients; new SVP hires in supply chain and APAC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.